Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer

(Dec. 2021) Recently, executive recruitment firm Caliber Associates placed Theresa LaVallee, Ph.D. as the Chief Development Officer at Coherus BioSciences (Nasdaq: CHRS) in Redwood City, Ca. Dr. LaVallee will serve as a member of the Company’s executive leadership team and oversee all regulatory matters and product development functions, reporting to Denny Lanfear, President and CEO of Coherus.

“Theresa is a terrific addition to Coherus at a time when we are increasingly focused on our immuno-oncology pipeline, particularly combinations with toripalimab, our PD-1 inhibitor,” said Mr. Lanfear. “She is a seasoned executive with a proven track record of success in the end-to-end discovery and development of drugs and diagnostics for cancer. With her scientific and regulatory expertise, she will play a critical role in the growth of our immuno-oncology development capabilities.”

“Coherus’ lead immuno-oncology asset, toripalimab, is establishing a compelling clinical profile in late-stage trials. PD-1 inhibitors such as toripalimab are expected to play a long-term foundational role in immuno-oncology drug development as the backbone of novel combination treatments,” said Dr. LaVallee. “I look forward to working with the team at Coherus and with the Company’s world-class Scientific Advisory Board to help Coherus become a leader in immuno-oncology and to advance novel treatments for cancer patients.”

Dr. LaVallee brings more than 25 years of drug discovery and development experience. Most recently, Dr. LaVallee was Vice President, Translational Medicine and Regulatory Affairs at the Parker Institute for Cancer Immunotherapy where she provided scientific leadership for clinical strategy for development of novel immuno-oncology therapies and helped establish the institute’s clinical, translational and regulatory organization. Previously, she held executive roles at Kolltan Pharma and Celldex Therapeutics. From 2008 – 2013, she was a member of the immuno-oncology team at AstraZeneca (MedImmune) developing checkpoint inhibitors and related diagnostics. She earned her Ph.D. from the University of California, Los Angeles and her bachelor’s degree from the University of California, Santa Barbara.

About Coherus BioSciences
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system. Coherus’ strategy is to build a leading immuno-oncology franchise in the United States and Canada funded with cash generated by its commercial biosimilar business.

Life Sciences Recruiters

Caliber Associates, founded in 1988, is a leading search firm focused exclusively in the life science sector. Caliber Associates has partnered with over 175 leading life science companies and has completed upwards of 800 searches, placing strategic executives with broad therapeutic and functional reach.

Mr. Hochberg leads the firm, recruiting CEOs, Board Members, C-level and strategic functional leaders for emerging life science companies and global biopharmaceutical companies. He has assembled a team of highly experienced, results driven search professionals. Prior to his search career, he held strategic human resource leadership roles with Rhône-Poulenc Rorer, FMC Corp. and Shell Oil Co.

Share This Article